Phase II study of neoadjuvant bevacizumab with weekday-on/weekday-off capecitabine and radiation for locally advanced rectal cancer
Phase 2
Recruiting
- Conditions
- rectal cancer
- Registration Number
- JPRN-UMIN000011365
- Lead Sponsor
- Osaka City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Not provided
Exclusion Criteria
prior radiotherapy, chemotherapy or any molecular targeting therapy for rectal cancer; no other co-existing malignancy or malignancy within the last five years prior to enrollment other than non-melanoma skin cancer or in situ carcinoma of the cervix; no severe concurrent medical or psychiatric illness; no a known hypersensitivity to the study drugs; and none of the patients were pregnant or lactating.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pCR rate
- Secondary Outcome Measures
Name Time Method response rate,rate of R0 resection, 3-years survival rate